Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study.
Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...
The youngest population under 50 years old (P50) with lung cancer (LC) in the French nationwide real-life KBP cohorts: Evolution since 2000. Clinical outcomes of maintenance durvalumab after ...
Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
Announces majority investment in NGS bioinformatics solution provider Ridom GmbH New NGS microbiology solutions for hygiene testing and epidemiological studies HAI (Hospital-Acquired Infections) ...
From Days to Hours: MicroGenDX Ushers in Next-Day NGS Results ORLANDO, FLORIDA / ACCESS Newswire / July 7, 2025 / MicroGenDX, a national leader in molecular diagnostics, announces the integration of ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results